Tether has invested in Tenstorrent's $1.5 billion funding round, a company focused on AI processors and computing infrastructure. This funding values Tenstorrent at $6.2 billion and aims to expand developer access to AI computing power. The investment highlights growing interest in AI hardware innovation and could accelerate advancements in AI technology.
The news about OpenZeppelin adding Chainlink cross-chain capabilities provides context for readers interested in the crypto sector. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 21, 2026 05:11 WIB: out of 50 major cryptocurrencies, 44 rose and 5 fell today. Balancer (BAL) led gains with a 11.14% increase to Rp16.297, surpassing EOS (EOS.IO) which rose 8.13% to Rp12.649, while VeChain (VET) increased 7.09% to Rp129, with a nearly balanced Pluang order activity of 49% sell and 51% buy and a notably longer typical hold time of 148 days compared to BAL's 85 and EOS's 87 days.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
